Jaguar动物健康 JAGX 深 沪
已收盘 12-12 16:00:00 美东时间
1.35
-0.090
-6.25%
华盛通- 最 高1.50
- 今 开1.45
- 成交量 18.93万股
- 最 低 1.32
- 昨 收 1.44
- 总市值 293.61万
- 52周最高 33.25
- 市盈率 静 --
- 换手率 8.70%
- 52周最低 1.00
- 委 比 9.53%
- 总股本 217.49万
- 历史最高 2501887500.00
- 量 比 0.30
- 振 幅 12.50%
- 历史最低 1.32
- 每 手 1
- 风险率 8.40%
个股概要
财务分析
公司资料
相关新闻
分红派息
- 分时图
- 日k
- 周k
- 月k
相关新闻
更多Jaguar Health Executes Strategic Stock Exchange Agreements
Jaguar Animal Health ( ($JAGX) ) has shared an update. On June 27, 2025, Jaguar...
12-13 06:20
Jaguar Health Secures FDA Conditional Approval Extension For Canalevia-CA1 To Treat Canine Chemotherapy-Induced Diarrhea Through December 2026
Conditional approval extended through December 2026 for the treatment of CID in dogs CID confirmatory effectiveness trial expected to conclude in February 2026, ahead of FDA's June deadline - 51 dogs enrolled to date; ~49 more expected
12-10 22:05
FDA Approves Renewal Of Canalevia-CA1
Conditional approval extended through December 2026 for the treatment of CID in dogsCID confirmatory effectiveness trial expected to conclude in February 2026, ahead of FDA's June deadline - 51 dogs enrolled to date; ~49
12-10 22:05
Jaguar Health's Napo Therapeutics Requests Advice From EMA's CVMP Regarding Its Plan To Pursue Approval Of Canalevia In EU For Treatment Of General Diarrhea In Dogs
Jaguar's requesting advice from EMA on EU approval pathway for general diarrhea of FDA conditionally approved Canalevia®A novel non-antibiotic approach to diarrhea treatment is important because there are no
12-02 22:05
Jaguar Health Submits All Amended Protocol To FDA For Its Current Clinical Studies Of Crofelemer In Pediatric MVID Participants
Jaguar Health, Inc. (NASDAQ:JAGX) (Jaguar) family company Napo Pharmaceuticals (Napo) today announced that, in support of a possible expedited approval pathway for crofelemer for treatment of intestinal failure in
11-20 22:04
Jaguar Health Amends Royalty Interests and Note Terms
An announcement from Jaguar Animal Health ( ($JAGX) ) is now available. On Nove...
11-20 02:58
Jaguar Health Q3 EPS $(6.28) Misses $(5.08) Estimate, Sales $3.083M Miss $3.730M Estimate
Jaguar Health (NASDAQ:JAGX) reported quarterly losses of $(6.28) per share which missed the analyst consensus estimate of $(5.08) by 23.62 percent. This is a 76.08 percent increase over losses of $(26.25) per share from
11-17 21:04
Jaguar Animal Health Secures $10.8M Note Agreement
An update from Jaguar Animal Health ( ($JAGX) ) is now available. On November 1...
11-15 06:17
Jaguar Health To Present An Abstract With Partial Results From An Ongoing Investigator-Initiated Trial Of Crofelemer Demonstrating Disease Progression Modification And Reduction Of Total Parenteral Support In Pediatric Intestinal Failure Patients Ranging Between 12% To 37%
Results of ongoing investigator-initiated proof-of-concept trial of crofelemer in United Arab Emirates (UAE) demonstrate disease progression modification and reduction of total parenteral support (PS) in pediatric
11-06 22:09
12 Health Care Stocks Moving In Thursday's After-Market Session
Gainers Aditxt (NASDAQ:ADTX) shares increased by 28.3% to $0.89 during Thursda...
10-10 05:06
